SBIR-STTR Award

Virus-Like-Particle (VLP) Vaccine for Chicken Infectious Anemia
Award last edited on: 5/30/2023

Sponsored Program
SBIR
Awarding Agency
USDA
Total Award Amount
$585,920
Award Phase
2
Solicitation Topic Code
8.3
Principal Investigator
Linda O Michel

Company Information

Larad Inc

132 East Liberty Street
Wooster, OH 44691
   (330) 264-6441
   N/A
   www.laradinc.com
Location: Single
Congr. District: 16
County: Wayne

Phase I

Contract Number: 2017-33610-27182
Start Date: 9/1/2017    Completed: 4/30/2018
Phase I year
2017
Phase I Amount
$99,245
The human population relies on food animals as a major source of high quality protein. Maintaining the health of these animals is of critical importance to good human nutrition worldwide. Chicken anemia virus (CAV) is an important immunosuppressive pathogen of poultry. Our Phase I goal is to create a CAV virus-like-particle (VLP) that will offer a less expensive source of high quality antigens that can be more consistently produced for CAV diagnostics and vaccines. CAV is the cause of chicken infectious anemia (CIA), a contagious immunosuppressive disease that causes a substantial economic impact on the poultry industry due to reduced flock performance. The quality of current CAV vaccines is inconsistent and they do not provide long lasting immunity. LARAD will produce recombinant baculoviruses expressing the VP1 and VP2 genes of CAV. These will be used to co-infect Sf9 cells to generate a CAV-VLP. LARAD will also complete the safety and purity experiments required for Conditional Licensure of the vaccine by the USDA Center for Veterinary Biologics. In addition, the CAV-VLP will be tested for its utility as an antigen in an ELISA diagnostic assay. A commercial opportunity exists for a CAV-VLP vaccine because CIA is a significant problem in the poultry industry. Patents on baculovirus expressed CAV-VLP have expired without successful commercialization of the product, which has the potential to replace current live-attenuated vaccines, a $2.3 million market.

Phase II

Contract Number: 2018-33610-28579
Start Date: 9/1/2018    Completed: 8/31/2020
Phase II year
2018
Phase II Amount
$486,675
The human population relies on food animals as a major source of high quality protein. Maintaining the health of these animals is of critical importance to good human nutrition worldwide. Chicken anemia virus (CAV) is an important immunosuppressive pathogen of poultry. We are proposing to improve vaccines and diagnostics for this pathogen to improve animal health. Chicken infectious anemia (CIA) is the disease caused by CAV, a ubiquitous virus found in all poultry producing regions worldwide. CAV has been controlled by vaccinating breeder flocks one time with a live attenuated vaccine at about 12 weeks of age. The resulting maternal immunity is transferred to chicks and protects them against CAV during the critical early development of their immune systems. However, the immunity to CAV in the breeder flock declines over time, leaving chicks vulnerable to infection. A vaccine is needed that can be used multiple times to create a longer lasting immunity to CAV in breeder flocks. Although CAV often causes only a subclinical disease in young chicks, the resulting infection results in reduced growth rate, poor feed efficiency, lower weight uniformity and most importantly immune suppression that leaves chicks susceptible to secondary and opportunistic infections. Vaccine companies are currently producing live CAV vaccines in cell culture or embryonated chicken eggs. In addition to being expensive and time consuming, the quantity of antigen produced through this method is highly variable. In the poultry vaccine market, profit margins are very tight. Producing CAV vaccine using conventional methods is not only expensive but is a bottleneck in the production of these vaccines that can cause an inability to meet market demand. CAV vaccine manufacturers have also had problems with CAV contamination in their other vaccines. This has caused some very expensive decontamination efforts and loss of the contaminated vaccine lots. Our proposal to produce a CAV vaccine using genetic engineering is one solution to these problems. No infectious CAV is ever used in our system and production quality and quantity is improved.